Stock Abbreviation: Qianyuan Pharmaceutical
Stock Code: 300254
Shanxi Qianyuan Pharmaceutical Group Co., Ltd.
2026 Restricted Stock Incentive Plan
(Draft)
August 2026
Statement
The Company and all directors guarantee that this incentive plan and its summary contain no false records, misleading statements, or major omissions, and assume individual and joint legal liability for their truthfulness, accuracy, and completeness.
Special Notice
-
This incentive plan is formulated in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Administrative Measures for Equity Incentives of Listed Companies, the Continuous Supervision Measures for Listed Companies on the ChiNext Market, the Listing Rules for Stocks on the ChiNext Market of the Shenzhen Stock Exchange, the Guidelines No. 1 for Self-Regulation of Listed Companies on the ChiNext Market—Business Handling, other relevant laws, regulations, and normative documents, and the Articles of Association of Shanxi Qianyuan Pharmaceutical Group Co., Ltd.
-
The incentive tool adopted in this plan is restricted stock (Type I restricted stock). The source of the shares is the Company's A-share common stock issued to the incentive targets.
-
The total number of restricted shares to be granted under this plan shall not exceed 17.00 million shares, representing 6.61% of the Company's total share capital of 257.208563 million shares at the time of the announcement of this draft. Of this, 14.00 million shares will be granted initially, accounting for 5.44% of the total share capital and 82.35% of the total equity granted. The reserved portion is 3.00 million shares, accounting for 1.17% of the total share capital and 17.65% of the total equity granted.
As of the disclosure date of this announcement, after excluding the Type I restricted shares already repurchased and cancelled, the number of shares under the 2024 incentive plan is 6.64 million, and the number of shares under the 2025 incentive plan is 9.05 million. Including the 17.00 million shares under this plan, the total number of underlying shares involved in all historical and current incentive plans is 32.69 million, representing 12.71% of the total share capital at the time of this announcement.
The total underlying shares involved in all effective equity incentive plans do not exceed 20% of the Company's total share capital. Under this plan, 7.50 million shares are proposed to be granted to Chairman Huang Lequn, accounting for 2.92% of the total share capital; combined with shares granted in 2024, this totals 3.03%. As a core decision-maker, Mr. Huang Lequn's stability is vital to the Company's R&D strategy and governance. Based on his historical contributions and the irreplaceability of his role, the Company grants him more than 1% of the total share capital to bind his interests with the Company's long-term development. According to Article 14 of the Administrative Measures for Equity Incentives of Listed Companies, this grant requires approval by a special resolution of the shareholders' meeting.
If the Company undergoes capital reserve conversion, stock dividends, share splits or consolidations, or rights issues between the announcement of this draft and the registration of the restricted shares, the grant quantity will be adjusted accordingly.
-
The grant price (including reserved) of the restricted shares is 6.27 yuan/share. If the Company undergoes capital reserve conversion, stock dividends, share splits or consolidations, rights issues, or dividend distributions between the announcement of this draft and the registration of the restricted shares, the grant price will be adjusted accordingly.
-
The total number of incentive targets for the initial grant is 49, including directors, senior management, and core technical and management personnel serving in the Company (including branches and subsidiaries) at the time of this announcement.